[225Ac]DOTA-YS5

N/A

Report date: 2025/10/31 15:08:09

Base Information

Drug Name[225Ac]DOTA-YS5
Drug Alias Name[225Ac]DOTA-YS5
ClassificationRadiation-emitting products > Radioactive therapeutic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Radiation-emitting products > Nuclides > Actinium > 225Ac +[4
Mechanisms of ActionPositron-emission tomography enhancersAnti-MCP
TargetsMembrane cofactor protein
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A